Premium
The role of thrombophilia testing in women with adverse pregnancy outcomes
Author(s) -
Unterscheider Julia,
Kane Stefan C,
Cutts Briony,
Savoia Helen,
Said Joanne M
Publication year - 2017
Publication title -
the obstetrician and gynaecologist
Language(s) - English
Resource type - Journals
eISSN - 1744-4667
pISSN - 1467-2561
DOI - 10.1111/tog.12366
Subject(s) - thrombophilia , medicine , pregnancy , obstetrics , placental abruption , context (archaeology) , gynecology , gestation , thrombosis , surgery , paleontology , genetics , biology
Key content Thrombophilias, whether inherited or acquired, have been linked to adverse pregnancy outcomes, such as pre‐eclampsia, placental abruption, fetal growth restriction, stillbirth, thrombosis and recurrent pregnancy loss in many but not all case–control studies. Prospective cohort studies have confirmed that the majority of women who carry inherited thrombophilias do not experience adverse pregnancy outcomes. Thrombophilia testing is expensive and the positive yield of such investigations, in particular with respect to informing management in a subsequent pregnancy, is low. This review critically evaluates the benefit of thrombophilia testing in the obstetric setting and provides guidance with respect to care of women in a subsequent pregnancy following an adverse outcome.Learning objectives To understand the relationship between the various thrombophilias and pregnancy complications. To appreciate the appropriate role of screening for and treating thrombophilias in the context of such pregnancy complications.Ethical issues Should thrombophilia testing following adverse pregnancy outcome be informed by specific factors in the clinical history? Can placental histopathology help guide selection of women requiring further assessment? Thrombophilias may be associated with thromboembolic complications in later life – is it therefore ethical to withhold testing in women with a history of adverse pregnancy outcomes?